...
机译:HR-NBL1 / Siopen试验中的抗GD2抗体CH14.18 / CHO +/-IL2的免疫疗法改善了高危神经母细胞瘤患者的结果与历史控制相比
St Anna Kinderkrebsforsch eV Studies &
Stat Integrated Res &
Projects S2IRP Vienna Austria;
St Anna Kinderkrebsforsch eV Studies &
Stat Integrated Res &
Projects S2IRP Vienna Austria;
Gustave Roussy Children &
Adolescent Oncol Dept Paris France;
Univ Hosp Southampton NHS Fdn Trust Southampton Hants England;
Fdn IRCCS Ist Nazl Tumori Paediat Oncol &
Haematol Milan Italy;
Hosp Univ &
Politecn La Fe Paediat Oncol &
Haematol Valencia Spain;
Tel Aviv Univ Schneider Childrens Med Ctr Israel Sackler Fac Med Paediat Oncol &
Haematol Petah;
Univ Hosp Ghent Paediat Oncol &
Haematol Ghent Belgium;
Our Ladys Childrens Hosp Paediat Haematol Oncol Crumlin Dublin Ireland;
Sydney Childrens Hosp Paediat Oncol &
Haematol Randwick NSW Australia;
Queen Mary Hosp Dept Paediat &
Adolescent Med Hong Kong Hong Kong Peoples R China;
Natl Hosp Norway Paediat Oncol &
Haematol Oslo Norway;
Univ Hosp Aarhus Paediat Oncol Haematol Aarhus Denmark;
Univ Hosp Lausanne Paediat Oncol Haematol Lausanne Switzerland;
Apeiron Biol AG Vienna Austria;
AIT Austrian Inst Technol GmbH Ctr Hlth &
Bioresources Graz Austria;
St Anna Kinderkrebsforsch eV Tumour Biol Vienna Austria;
Paris Descartes Univ Necker Enfants Malad Hosp Dept Pediat Surg Paris France;
Univ Hosp Ghent Paediat Oncol &
Haematol Ghent Belgium;
Univ Med Greifswald Paediat Oncol &
Haematol Greifswald Germany;
机译:HR-NBL1 / Siopen试验中的抗GD2抗体CH14.18 / CHO +/-IL2的免疫疗法改善了高危神经母细胞瘤患者的结果与历史控制相比
机译:HR-NBL1 / Siopen试验中的抗GD2抗体CH14.18 / CHO +/-IL2的免疫疗法改善了高危神经母细胞瘤患者的结果与历史控制相比
机译:白细胞介素2具有抗GD2抗体CH14.18 / CHO(DINUTUXIMABβ)高危神经母细胞瘤(HR-NBL1 / SIOPEN):多期,随机,第3阶段试验
机译:长期输注抗GD2抗体ch14.18 / CHO治疗的高危神经母细胞瘤患者的耐受性反应和结果
机译:Dinutuximabβ的免疫治疗在Siopen高危神经母细胞瘤1试验中的作用调查(HR-NBL1)